Letter: vedolizumab or a second anti‐TNF—no difference in efficacy for primary biologic failures with IBD. Authors' reply

LINKED CONTENT This article is linked to Rundquist et al and Demarzo papers. To view these articles, visit https://doi.org/10.1111/apt.16193 https://doi.org/10.1111/apt.16301